Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoViricides, Inc. on October 29, 2018. The report discloses a corporate governance change involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
- Board Election: Effective October 29, 2018, the Board of Directors elected James Sapirstein as a new Independent Member.
- Committee Assignments: Mr. Sapirstein will serve on the Audit, Compensation, and Nominating Committees.
- Executive Agreement: Mr. Sapirstein executed the Company's standard Director Retainer Agreement (Exhibit 10.1).
Management Commentary and Background
Management highlighted Mr. Sapirstein's extensive background to justify his appointment:
- Experience: Over 30 years in the pharmaceutical industry with involvement in nearly two dozen product launches.
- Recent Roles: Former CEO of ContraVir Pharmaceuticals (2014–2018), Alliqua Therapeutics, and Tobira Therapeutics.
- Industry Focus: Significant experience in HIV/AIDS, Hepatitis B, and infectious diseases, including leadership roles at Eli Lilly, Hoffmann-LaRoche, Bristol Myers Squibb, and Gilead Sciences.
- Board Service: Current board positions at Enochian Biosciences, RespireRx Pharmaceuticals, and Leading Biosciences; Chairman of BioNJ.
Key Facts for Investor Verification
- Confirm the effective date of James Sapirstein's board membership (October 29, 2018).
- Review the attached Director Retainer Agreement (Exhibit 10.1) for specific compensation terms.
- Verify Mr. Sapirstein's current board affiliations and potential conflicts of interest with competitors or partners.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial status.